Q2 saw record revenues and profitability, driven by strong Buvidal and BRIXADI growth, robust cash flow, and expanding European launches. Regulatory remediation for Oclaiz is underway, with key pipeline catalysts expected in H2.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.